UCLA Technology Development Group (UCLA TDG) presents The Los Angeles Bioscience Ecosystem Summit 2021 (LABEST pronounced L-A Best). This event is the premier showcase for bioscience innovation in Los Angeles County. A true collaboration with colleagues from across the county, LABEST presents promising academic research, entrepreneurial faculty investigators, as well as local start- up companies. The goal is to promote awareness of the growing life science entrepreneurial ecosystem in Los Angeles in order to foster partnerships with the biopharma industry.

The pandemic demonstrated the need to quickly translate discoveries into real world products. In this virtual summit we bring together people that make a difference: researchers, hospital CEOs, investors and industry the entire ecosystem needed for drug development and commercialization, said Amir Naiberg, Vice Chancellor, CEO & President, UCLA TDG.

The conference is entirely virtual this year. Throughout the summit, faculty members present the latest scientific breakthroughs, which may lead to the critical therapies of tomorrow. Leading bioscience translational research programs and start-ups will be showcased where Southern California Institutions have significant expertise, pioneering research and resource commitments directed towards developing innovative patient therapies.

LABEST is led by Mark Wisniewski, Senior Director, Bio Pharmaceuticals, UCLA TDG. He adds, We have many leaders who will be providing different perspectives at LABEST on LAs significant progress as a bioscience ecosystem and successful drug development collaborations including Anne Rimoin Professor of Epidemiology who is a keynote speaker, Maria Millan CEO of California Institute of Regenerative Medicine, Arie Belldegrun, Chairman of Bellco Capital, Steven Rosen, Provost and Chief Scientific Officer of the City of Hope and Johnese Spisso, CEO of UCLA Health and President of UCLA Hospital.

LABEST INFORMATION (images on last page) #UCLALABEST2021 @UCLATDG

DATES:Tuesday May 25, Wednesday May 26 and Thursday May 27, 2021

TIME: 9:00AM 5:00PM Pacific Standard Time

LABEST OFFICIAL WEBPAGE https://tdg.ucla.edu/la-best-la-bioscience-ecosystem-summit-2021

REGISTRATION

General Tickets are currently $95 and increase to $125 after May 15th. The cost includes all 3 Days of the LABEST Conference. Registration link: https://tdg.ucla.edu/la-best-la-bioscience-ecosystem-summit-2021

WHERE

This is a completely virtual event. Registered attendees can access the LABEST virtual conference at https://labest2021.vfairs.com/

AGENDA HIGHLIGHTS | View the Latest Agenda Here

KEYNOTE SPEAKERS

CONFERENCE HIGHLIGHTS

LABEST SHORT TALK/PANEL DESCRIPTIONS

Talk/Panel Title

Description

Keynote: Why LA

Eric Esrailian and Gene Sykes

"Why LA": Los Angeles' attraction as a bioscience ecosystem, its exciting growth, competitive advantages, and its future including hosting the 2028 Summer Olympics, LA28.

Keynote: Martin Jarmond

Every player has their part. Teamwork and responsibility are key.

Keynote: Anne Rimoin

COVID-19 and Beyond

How to stop pandemics before they start

Hospital CEOs Sharing Innovations Panel

CEOs of Los Angeles' hospital systems will share their best practices and resulting innovations to address the COVID-19 pandemic and how their collaborative efforts will shape the future of hospital systems and the health of Los Angeles County.

Meet Leaders in the Business of Life Sciences

Biopharma leaders will address scientific innovation, drug development, financing andstartups trends in Los Angeles.

Growth and Retention of Biotech Start-ups in LA

Bioscience CEO will discuss their experiences, decisions, challenges and future opportunities with being located in Los Angeles.

CIRM Strategic Priorities and Opportunities Beyond 2020

With the passage of Prop 14, an additional $5.5 billion dollars have been allocated to fund stem cell research. Leaders in the field will discuss strategy and new opportunities in neuropsychiatric and other disorders.

Immuno-Oncology 2021 and Beyond Panel

After three decades of research, immune-based therapies have become potent new cancer treatments. Recent advances are focused on furthering our understanding of the mechanisms of action and improving access.

Startup Engines: Academic Industry Partnerships

Learn about new partnerships and models of collaboration between academia and industry to advance innovative research into new bioscience startups.

Moving Microbes from Bench to Bedside Panel

An expert-led discussion of the promise of microbial-based treatments for disease while addressing the major obstacles in clinical translation and integrating microbiome-based treatments into the standard of care.

Emerging Therapeutics in Neuroscience Panel

Recent advances in neuroscience will be discussed by a panel of experts seeking to impact these frequently unmet medical needs.

Scaling Gene and Cell Therapies to Reach More Patients Globally Panel

Due to a complex, multi-step treatment journey, there are numerous logistical challenges when it comes to expanding the reach of cell and gene therapies. How can we leverage bio manufacturing speed and scale to unlock the potential of cell and gene therapies and ensure they can get to the patients who need them?

Venture Capital and Syndication In Los Angeles

Learn how prominent Venture Capitalists are focusing on Los Angeles bioscience innovation and the how the increasing availability of capital is generating robust innovative startups in Los Angeles.

Advancing Inclusive Research

In order to enhance the accessibility and affordability of effective therapies, new models for the conduct of clinical trials will be discussed.

Amgen Research & Development/ Academic Strategies

Industry leaders discuss how to strategically work with academia to develop a pipeline for research, development and talent.

Amgen Ventures and Business Development in Los Angeles

How much bioscience business development is really happening in Los Angeles?

How Kite is Building a Global CAR T Franchise Out of LA

Learn how Kite's focus on cell therapy to treat cancer has advanced industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to treat both hematological cancers and solid tumors.

Visit link:
Los Angeles Area Bioscience Academic Institutions, Researchers, Industry and Investors Converge at LABEST May 25 27, 2021 - BioSpace